CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

Detailed price information for Broadridge Financial Solutions Llc (BR-N) from The Globe and Mail including charting and trades.

Security National Financial Corporation (SNFC) (NASDAQ symbol "SNFCA") announced financial results for the quarter ended September 30, 2025. For the ...

Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) ...

Record-setting quarter, one more example of our strong growth and continued diversification.TPV at record high of US$10.4 billion, growing nearly ...

Presenting INTASYL siRNA Drug Technology King of Prussia, Pennsylvania–(Newsfile Corp. – November 17, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA ...

Also included in cash used in operations for the third quarter of 2025 is inventory financing payments of $1,378,000 for golf cart purchases of Venom under our financing agreement, which is expected ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell ...

DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the third quarter ended September 30, 2025, along with ...

This package summarizes data from the Brokerage, Dealers' and Bank reports, looking at trends across the financial advice ...

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's ...